Ultrasound criteria and CA 125 as predictive variables of ovarian cancer in women with adnexal tumors

Ultrasound in Obstetrics and Gynecology

Volumn 40, Issue 3, 2012, Pages 360-366

  Hartman, C A ^a   Juliato, C R T ^a   Sarian, L O ^a   Toledo, M C ^a   Jales, R M ^a   Morais, S S ^a   Pitta, D D ^a   Marussi, E F ^a   Derchain, S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

adnexal; CA 125; performance; tumors; ultrasonography

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; BLOOD; COLOR ULTRASOUND FLOWMETRY; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; FEMALE; HUMAN; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; CA-125 ANTIGEN; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 84865470598     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.11201     Document Type: Article

References (24)

1. Hilger WS, Magrina JF, Magtibay PM,. Laparoscopic management of the adnexal mass. Clin Obstet Gynecol 2006; 49: 535-548.
2. McDonald JM, Modesitt SC,. The incidental postmenopausal adnexal mass. Clin Obstet Gynecol 2006; 49: 506-516.
3. Greenlee RT, Kessel B, Williams CR, Riley TL, Ragard LR, Hartge P, Buys SS, Partridge EE, Reding DJ,. Prevalence, incidence, and natural history of simple ovarian cysts among women > 55 years old in a large cancer screening trial. Am J Obst Gynecol 2010; 373: 1-9.
4. Torres JC, Derchain SF, Faundes A, Gontijo RC, Martinez EZ, Andrade LA,. Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer. Sao Paulo Med J 2002; 120: 72-76.
5. van den Akker PA, Aalders AL, Snijders MP, Akker PAJ, Luivers KS, Samlal RA, Vollebergh JH, Massuger LF,. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses. Gynecol Oncol 2010; 116: 384-388.
6. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L,. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: A multicenter study by the international ovarian tumor analysis group. J Clin Oncol 2005; 23: 8794-8801.
7. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I,. Terms, definitions and measurements to describe to sonographic features of adnexal tumors: a consensus opinion from the international ovarian tumor analysis (IOTA) group. Ultrasound Obstet Gynecol 2000; 16: 500-505.
8. Van Holsbeke C, Van Calster B, Testa AC, Domali E, Lu C, Huffel SV, Valentin L, Timmerman D,. Prospective internal validation of mathematical models to predict malignancy in adnexal masses: results from the international ovarian tumor analysis study. Clin Cancer Res 2009; 15: 684-691.
9. Timmerman D, Van Calster B, Jurkovic D, Valentin L, Testa AC, Bernard JP, Van Holsbeke C, Huffel SV, Vergote I, Bourne T,. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol 2007; 25: 4194-4200.
10. Van Holsbeke C, Van Calster B, Bourne T, Ajossa S, Testa AC, Guerriero S, Fruscio R, Lissoni AA, Czekierdowski A, Savelli L, Van Huffel S, Valentin L, Timmerman D,. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin Cancer Res 2012; 18: 815-825.
11. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, Paladini D, Van Calster B, Vergote I, Van Huffel S, Valentin L,. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008; 31: 681-690.
12. Timmerman D, Van Calster B, Testa AC, Guerriero S, Fischerova D, Lissoni AA, Van Holsbeke C, Fruscio R, Czekierdowski A, Jurkovic D, Savelli L, Vergote I, Bourne T, Van Huffel S, Velentin L,. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation by the IOTA group. Ultrasound Obstet Gynecol 2010; 36: 226-234.
13. Scully R, Sobin L,. Histological Typing of Ovarian Tumours, volume 9 Springer: New York, Berlin, 1999.
14. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2011; http://www.R-project.org/ [Accessed 17 November 2011].
15. Hothorn T, Hornik K, Zeileis A,. (2006). Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006; 15: 651-674. (Reprint available from: http://statmath.wuwien.ac.at/~zeileis/papers/Hothorn+ Hornik + Zeileis-2006.pdf [Accessed 17 November 2011].).
16. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L,. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007; 99: 1706-1714.
17. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell Jr JR,. Predicting risk of malignancy in adnexal masses. Obstet Gynecol 2010; 115: 687-694.
18. Aktürk E, Karaca RE, Alanbay I, Dede M, Karasahin E, Yenen MC, Baser I,. Comparison of four malignancy risk índices in the detection of malignant ovarian masses. J Gynecol Oncol 2011; 22: 177-182.
19. Patrelli TS, Beretta R, Gizzo S, Pezzuto A, Franchi L, Lukanovic A, Nardelli GB, Modena AB,. CA 125 serum values in surgically treated endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy rate. Fertil Steril 2011; 95: 393-396.
20. He RH, Yao WM, Wu LY, Mao YY,. Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases. Arch Gynecol Obstet 2011; 283: S107-S110.
21. McLemore MR, Aouizerat BE, Lee KA, Chen L, Cooper B, Tozzi M, Miaskowski C,. A comparison of the cyclic variation in serum levels of CA 125 across the menstrual cycle using two commercial assays. Biol Res Nurs 2012; 14: 250-256.
22. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, Farias-Eisner R,. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200: 639e1-5.
23. Henessy BT, Coleman RL, Markman M,. Ovarian cancer. Lancet 2009; 374: 1371-1382.
24. Permuth-Wey J, Sellers TA,. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472: 413-437.